The purpose of this study is to observe the safety and efficacy of Aspirin combined with Trametinib and Dalafenib in the treatment of advanced BRAF V600E mutated non-small cell lung cancer (NSCLC)
Inoperable stage IIIB-IV patients with non-small cell lung cancer;
BRAF V600E mutation;
Dabrafenib and Trametinib are planned for treatment, and the survival period is expected to be more than 3 months;
ECOG PS 0/1;
The patient is currently receiving other anticoagulant therapy;
The patient was previously treated with systemic anti-NSCLC;
The patient had other positive driver mutations, including EGFR, ALK, ROS1, MET14, RET, etc.
The patient had contraindications for dalafenib or trametinib and aspirin use;